Praziquantel + Moxidectin (Quest Plus)

Praziquantel combined with moxidectin, marketed as Quest Plus, represents the most potent broad-spectrum deworming option available for horses, combining exceptional larvicidal activity against encysted small strongyles with comprehensive tapeworm control. This combination product pairs moxidectin, a second-generation macrocyclic lactone with superior potency and duration compared to ivermectin, with praziquantel's proven efficacy against all equine tapeworm species. The unique larvicidal properties of moxidectin distinguish Quest Plus from other combination dewormers, making it particularly valuable for horses with suspected or confirmed encysted cyathostomin infections.

The mechanism of action leverages two complementary pathways to achieve comprehensive parasite elimination. Moxidectin binds with high affinity to glutamate-gated chloride channels found specifically in invertebrate nerve and muscle cells, causing sustained hyperpolarization that results in paralysis and death of susceptible parasites. Importantly, moxidectin demonstrates superior penetration into tissues where encysted strongyle larvae reside, enabling it to reach parasites that other dewormers cannot effectively target. Praziquantel increases tapeworm cell membrane permeability to calcium, inducing spastic paralysis and tegument damage that leads to rapid tapeworm destruction and expulsion.

Quest Plus is formulated as an oral gel in pre-calibrated syringes designed for weight-based administration. Each syringe delivers sufficient gel to treat horses up to 1,150 pounds at the labeled dose, with graduation marks allowing precise adjustment for horses of different sizes. The gel formulation facilitates administration and adherence to the oral mucosa, reducing the likelihood of rejection compared to some paste formulations. Each gram of gel contains 2% moxidectin and 12.5% praziquantel, delivering therapeutic doses of both active ingredients when administered according to the weight-based protocol.

The safety profile of Quest Plus requires more careful consideration than ivermectin-based combinations due to moxidectin's narrower safety margin. While well-tolerated in healthy adult horses at recommended doses, moxidectin carries specific contraindications in foals, debilitated horses, and certain miniature breeds that do not apply to ivermectin products. These considerations, combined with the product's particular efficacy against encysted larvae, position Quest Plus as a strategic tool for targeted parasite management rather than routine deworming. Veterinary guidance is strongly recommended to optimize the benefits of this powerful combination while minimizing risk.

The primary indication for Quest Plus centers on its unique ability to eliminate encysted small strongyle larvae while simultaneously providing tapeworm control. Small strongyles (cyathostomins) represent the most prevalent and potentially dangerous internal parasites in modern horse populations, with over 50 species capable of infecting equines. These parasites can encyst in the intestinal wall as early third stage (EL3), late third stage (LL3), and fourth stage (L4) larvae, creating a reservoir of infection that persists despite treatment with drugs that only target luminal stages. Moxidectin's exceptional tissue penetration enables it to reach and eliminate these encysted stages, providing larvicidal activity unmatched by ivermectin or fenbendazole at standard doses.

Larval cyathostominosis, the potentially fatal syndrome resulting from mass emergence of encysted larvae, represents a critical indication for Quest Plus use. This condition typically occurs in late winter or spring when large numbers of encysted larvae simultaneously emerge from the intestinal wall, causing severe inflammation, protein loss, diarrhea, colic, and potentially death. Horses with risk factors for larval cyathostominosis, including young age, recent introduction to a new property, or heavy pasture exposure, may benefit from strategic moxidectin treatment to reduce encysted larval burdens. However, treating horses with already massive encysted burdens carries its own risks of severe inflammatory reactions, requiring veterinary oversight.

Tapeworm control through the praziquantel component addresses all three equine cestode species: Anoplocephala perfoliata, the most common and clinically significant; Anoplocephala magna; and Paranoplocephala mamillana. A. perfoliata infections at the ileocecal junction are associated with spasmodic colic, ileal impaction, intussusception, and cecal rupture. The twice-yearly tapeworm treatment protocol recommended by parasitologists, typically in spring and fall, is conveniently accomplished with Quest Plus, which simultaneously addresses any nematode and bot infections present.

Beyond encysted larvae and tapeworms, Quest Plus effectively controls the full spectrum of adult nematode parasites. Large strongyles including the particularly dangerous Strongylus vulgaris, whose larvae migrate through mesenteric arteries causing potentially fatal verminous arteritis, are eliminated by the moxidectin component. Adult small strongyles in the intestinal lumen, pinworms causing perineal irritation, and hairworms of the stomach all fall within Quest Plus's spectrum of activity. The extended duration of moxidectin's effects, maintaining therapeutic tissue levels significantly longer than ivermectin, contributes to prolonged protection against reinfection.

Bot fly larvae represent an additional target addressed by Quest Plus. Administration following the first killing frost in autumn eliminates Gasterophilus larvae attached to the gastric mucosa before they complete development and cause significant gastric damage. The combination of bot control with tapeworm treatment and unmatched small strongyle larvicidal activity makes Quest Plus particularly valuable for strategic fall deworming in comprehensive parasite management programs designed by veterinary professionals.

Accurate weight-based dosing of Quest Plus is critically important due to moxidectin's narrower safety margin compared to ivermectin. The labeled dose delivers moxidectin at 400 micrograms per kilogram (182 mcg/lb) and praziquantel at 2.5 milligrams per kilogram (1.14 mg/lb) of body weight. The gel syringe is calibrated in 50-pound increments from 250 to 1,150 pounds, allowing precise dose adjustment. Each full syringe treats a horse up to 1,150 pounds; larger horses require partial doses from additional syringes, with calculations based on actual body weight.

Weight estimation requires particular diligence with Quest Plus to prevent overdosing in horses lighter than estimated or underdosing in horses heavier than estimated. Scale weights provide optimal accuracy and are strongly recommended, particularly for horses near the boundaries of syringe capacity or those with body types that weight tapes estimate poorly. When scales are unavailable, weight tapes should be used on dry horses at rest, with measurements taken at the heart girth. For Quest Plus specifically, rounding down rather than up provides a safety margin against overdose, as the product's potency provides effective parasite control across a range of body weights.

The standard treatment protocol involves single-dose administration at strategic intervals determined by fecal egg count results and seasonal factors rather than fixed calendar schedules. Quest Plus is not appropriate for routine frequent deworming; its potency and specific larvicidal activity are best reserved for targeted use. Many veterinary parasitologists recommend moxidectin-based products no more than once or twice annually, incorporating them into rotation programs that include other drug classes. Strategic timing often coincides with late fall or early spring when encysted larval treatment and tapeworm control are priorities.

Administration technique follows standard oral paste/gel protocols but warrants extra care given the product's potency. The horse's mouth should be empty of feed material before dosing. The syringe tip is inserted into the interdental space at the corner of the mouth, directed toward the base of the tongue. The plunger is depressed firmly to deposit gel as far back in the mouth as possible. Immediately raising the horse's head encourages swallowing. Unlike some paste dewormers, the gel formulation of Quest Plus may adhere to oral tissues rather than being easily ejected, improving dose delivery.

Missed doses should be administered when remembered, but the timing considerations for moxidectin differ from ivermectin. The extended duration of moxidectin's effects means that minor schedule variations have less impact on parasite control than with shorter-acting products. However, if Quest Plus is being administered as part of a targeted treatment for suspected encysted larvae, maintaining the planned protocol optimizes therapeutic outcomes. Veterinary guidance on rescheduling is warranted when significant deviations from planned timing occur.

Post-treatment monitoring is particularly important following Quest Plus administration in horses with suspected heavy encysted larval burdens. Signs of adverse reactions typically appear within 24-72 hours and may include colic, fever, diarrhea, or edema. Fecal egg count reduction testing two weeks post-treatment verifies efficacy against luminal parasites, while clinical improvement over subsequent weeks indicates successful larvicidal treatment of encysted stages. Horses failing to show expected egg count reductions may harbor resistant parasites requiring alternative management strategies.

Quest Plus is generally well-tolerated in healthy adult horses when administered at labeled doses, though the moxidectin component carries potential for adverse effects not seen with ivermectin-based products. The overall incidence of significant side effects is low in appropriate patient populations, but the specific risk profile necessitates careful patient selection and monitoring. Horse owners should be familiar with potential reactions ranging from expected parasite die-off effects to rare but serious toxicity signs.

Common side effects relate primarily to the death and expulsion of parasites rather than direct drug toxicity. Mild colic signs, soft manure, and transient appetite reduction may occur within 24-72 hours as dying parasites release contents and detach from intestinal tissues. These effects are typically self-limiting, resolving within one to three days without intervention. Horses treated for heavy parasite burdens, particularly those with significant encysted larvae populations, may experience more pronounced reactions as large numbers of larvae die within intestinal wall tissues, provoking inflammatory responses.

Moderate side effects associated with Quest Plus include localized or generalized edema, which may appear one to several days post-treatment. Ventral edema along the midline is most common and relates to death of Onchocerca microfilariae in subcutaneous tissues. This reaction is self-limiting and rarely requires treatment beyond monitoring. Transient depression, reduced water intake, or lethargy may occur in some horses, typically resolving within 48-72 hours. Persistent or worsening signs warrant veterinary evaluation to rule out more serious reactions.

Serious adverse effects, while uncommon in appropriate patients at correct doses, require awareness and prompt response. Signs of neurological toxicity including ataxia, weakness, depression progressing to recumbency, or blindness indicate overdose or abnormal drug sensitivity and constitute emergencies requiring immediate veterinary attention. Such signs are most likely in overdosed horses, foals given adult formulations, or miniature horses with aberrant drug metabolism. Severe colic signs, particularly those accompanied by fever, elevated heart rate, or signs of systemic illness, may indicate complications from massive parasite die-off including intestinal damage or endotoxemia.

Long-term side effects from periodic Quest Plus use at labeled doses have not been documented in healthy adult horses. The product is considered safe for repeated strategic use within appropriate parasite management programs. However, the potential for neurotoxicity in overdose situations or sensitive individuals necessitates the careful dose calculation, appropriate patient selection, and observation period following administration that distinguish moxidectin products from the more forgiving ivermectin class.

Use in foals under six months of age is strictly contraindicated for Quest Plus due to the narrower safety margin of moxidectin and limited safety data in very young horses. The blood-brain barrier may be incompletely developed in young foals, potentially allowing moxidectin greater central nervous system access than in adult horses. Foals requiring parasite treatment should receive age-appropriate products such as fenbendazole, ivermectin, or pyrantel, reserving moxidectin-containing products for horses over six months of age with appropriate body weight.

Debilitated, underweight, or severely parasitized horses represent significant risk populations for Quest Plus administration. Moxidectin's potency and extended duration mean that adverse effects, should they occur, may persist longer than with shorter-acting products. Horses in poor body condition may have altered drug distribution and metabolism, potentially increasing toxicity risk. Additionally, horses carrying extreme parasite burdens face substantial risk of severe reactions when large numbers of parasites die simultaneously. Such horses require veterinary evaluation and possibly staged treatment protocols beginning with lower-potency products.

Known hypersensitivity to moxidectin, praziquantel, or related compounds constitutes an absolute contraindication. Cross-reactivity between macrocyclic lactones means horses with previous adverse reactions to ivermectin or moxidectin should not receive Quest Plus without veterinary consultation. While true allergic reactions to these compounds are rare, any history of significant adverse effects following deworming warrants careful consideration of alternative products.

Specific breed and size restrictions apply to Quest Plus beyond those relevant to ivermectin products. Certain miniature horse breeding lines appear to carry genetic sensitivity to moxidectin, with documented cases of severe neurological toxicity at labeled doses. While not all miniature horses are affected, the unpredictability of this sensitivity has led many veterinarians to recommend avoiding moxidectin products in miniatures entirely or using them only with enhanced monitoring. Similarly, horses of any breed with body weights under 250 pounds require alternative products, as the syringe's minimum calibration mark delivers doses appropriate for 250-pound animals.

Breeding animal considerations warrant attention despite no specific label contraindications. Safety data for Quest Plus in pregnant mares is limited compared to ivermectin, leading some clinicians to prefer ivermectin-praziquantel combinations during pregnancy. The product should not be used in mares during the first three months of gestation without veterinary guidance. Stallion reproductive effects have not been documented, but as with any pharmaceutical, breeding soundness considerations may influence product selection for valuable breeding animals.

Concurrent administration of other macrocyclic lactone products with Quest Plus is contraindicated due to additive toxicity risk. Horses should not receive ivermectin, doramectin, or additional moxidectin formulations within several weeks of Quest Plus administration. The extended tissue persistence of moxidectin, which contributes to its therapeutic benefits, also means that overlap with subsequent macrocyclic lactone treatments should be avoided. Maintaining accurate deworming records prevents accidental duplicate dosing or premature administration of related products.

Interactions with drugs affecting the P-glycoprotein (P-gp) efflux transporter system warrant theoretical consideration. P-glycoprotein limits moxidectin penetration into the central nervous system, and inhibition of this transporter could potentially increase neurotoxicity risk. Drugs known to inhibit P-gp in other species include certain antifungals (ketoconazole, itraconazole), antibiotics (erythromycin), and cardiac medications (verapamil). While clinical significance of these interactions has not been established in horses, awareness is prudent when moxidectin-containing products are administered to horses receiving concurrent medications.

Other anthelmintic products may be used in appropriate rotation protocols but should not be combined simultaneously with Quest Plus. Pyrantel pamoate or tartrate, fenbendazole, and oxibendazole represent alternative drug classes commonly rotated with moxidectin to delay resistance development. These products should be administered at separate treatment intervals, typically weeks to months apart, according to veterinary-designed parasite management programs. Combining multiple dewormers in single treatment sessions provides no additional benefit and complicates monitoring for adverse reactions.

Sedatives, anesthetics, and other CNS-active drugs warrant mention given moxidectin's mechanism of action at neural chloride channels. While clinical interactions at therapeutic deworming doses are not documented, veterinarians should be informed of recent moxidectin administration before sedation or anesthesia. This is particularly relevant for horses undergoing emergency procedures shortly after deworming, where complete medication history aids in patient management and helps interpret any unusual responses to anesthetic protocols.

Competition drug testing considerations affect Quest Plus scheduling for performance horses. While neither moxidectin nor praziquantel is prohibited under most equine competition rules, detection times extend longer than for ivermectin products due to moxidectin's extended tissue persistence. Competition horses should receive Quest Plus well in advance of competition, with many governing bodies recommending withdrawal periods of several days to two weeks. Specific regulations vary by organization and change periodically; handlers should verify current requirements with their governing body and maintain documentation of all administered products for compliance verification.

Monitoring requirements following Quest Plus administration exceed those for ivermectin-based products due to the potential for more severe adverse reactions. All treated horses should be observed for 24-48 hours following administration, with particular attention to signs of neurological abnormalities, colic, or systemic illness. Horses treated for suspected heavy encysted larval burdens warrant closer monitoring over several days, as inflammatory reactions to dying larvae may not peak immediately. Access to emergency veterinary care should be confirmed before treating horses in remote locations.

Special population warnings define Quest Plus as a product requiring veterinary guidance for patient selection. The strict contraindication in foals under six months of age has been emphasized; this represents a non-negotiable restriction based on safety data. Horses over six months but under one year may be treated but should receive accurate weight-based dosing and enhanced monitoring. Geriatric horses with reduced hepatic or renal function may metabolize moxidectin differently, though specific dose adjustments have not been established. Consultation with a veterinarian is recommended for senior horses with known organ compromise.

Competition and performance horse considerations demand attention to extended withdrawal periods. Moxidectin's prolonged tissue persistence, while therapeutically advantageous, means detection windows extend well beyond those for ivermectin. FEI guidelines and USEF drug rules should be consulted for current recommendations, which typically suggest withdrawal periods of 14 days or longer depending on the specific competition level and testing sensitivity. Racing jurisdictions may have different standards. The strategic nature of Quest Plus use, typically once or twice annually, facilitates scheduling around competition calendars with appropriate planning.

Administration precautions emphasize accurate dosing and preventing accidental human or animal exposure. Operators should wear gloves when handling the product and wash hands thoroughly after administration. The syringe should be inspected before use to ensure the adjustment ring functions properly. Any gel contacting human skin should be washed off promptly. The product should be kept out of reach of children and other animals, particularly dogs, which may experience toxicity from macrocyclic lactones at equine deworming doses.

Long-term use considerations center on resistance prevention and strategic deployment of moxidectin's unique larvicidal properties. Routine frequent use of Quest Plus accelerates resistance development in small strongyle populations while squandering the product's special utility against encysted larvae. Veterinary parasitologists recommend reserving moxidectin for targeted strategic use within comprehensive programs incorporating fecal egg count monitoring, rotation to alternative drug classes, and pasture management. This approach preserves moxidectin efficacy for situations where its unique properties are truly needed while providing sustainable overall parasite control.

Storage requirements for Quest Plus ensure product stability and maintain efficacy throughout shelf life. The gel should be stored at controlled room temperature between 68°F and 77°F (20°C to 25°C), with brief excursions permitted between 59°F and 86°F (15°C to 30°C). Protection from light and moisture maintains gel consistency and active ingredient stability. Storage in climate-controlled environments such as residences, offices, or heated tack rooms meets these requirements. The product should not be stored in locations subject to temperature extremes, including unheated barns, vehicles, or areas receiving direct sunlight.

Handling safety reflects the greater potency of moxidectin compared to ivermectin. Operators should wear gloves during administration and avoid skin contact with the gel. While dermal absorption at incidental contact levels poses minimal human health risk, consistent protective practices represent good pharmaceutical handling standards. Any gel contacting skin should be washed off promptly with soap and water. The product should be handled carefully to prevent gel expulsion before administration, as the formulation is somewhat more fluid than typical paste dewormers.

Expiration dating and disposal require attention to both efficacy and environmental concerns. Shelf life extends approximately two years from manufacture for properly stored product, with specific expiration dates printed on each syringe. Partially used syringes should be discarded rather than saved for future use, as contamination and gel degradation may occur once the seal is broken. The gel should appear homogeneous without separation, discoloration, or unusual odor; any degraded product should be discarded without use.

Environmental disposal considerations are significant for moxidectin-containing products. Like all macrocyclic lactones, moxidectin is highly toxic to aquatic invertebrates and soil organisms at low concentrations. Unused product should not be disposed of in waterways, storm drains, or septic systems. Empty syringes can be discarded in household trash after ensuring all gel has been removed. Manure from recently treated horses contains drug residues and should not be spread near waterways, wetlands, or areas where runoff could reach aquatic environments. Composting treated manure for several weeks before land application reduces environmental impact.

Draft horse breeds present dosing challenges due to body weights potentially exceeding single-syringe capacity. Clydesdales, Percherons, Shires, and Belgians commonly weigh 1,600 to 2,200 pounds or more, while the Quest Plus syringe is calibrated to a maximum of 1,150 pounds. Accurate scale weights are essential for these breeds, as weight tape underestimation is common in draft body types. Multiple syringes may be required, with total dose calculated based on actual body weight. Despite higher total drug amounts, draft horses generally tolerate Quest Plus well when dosed correctly, as their larger body mass distributes the drug appropriately.

Miniature horses and miniature breeding lines represent the most significant breed-specific concern for Quest Plus. Documented cases of severe neurological toxicity, including ataxia, recumbency, and death, have occurred in certain miniature horse lines receiving labeled doses. The genetic basis for this sensitivity appears related to P-glycoprotein variants affecting drug transport across the blood-brain barrier, though not all miniatures carry affected genotypes. Given the unpredictability of individual sensitivity, many veterinarians recommend avoiding moxidectin products entirely in miniature horses, instead using ivermectin-based products with their wider safety margins.

Light horse breeds and warmbloods comprising the majority of sport and pleasure horses typically tolerate Quest Plus well within standard dosing parameters. These breeds generally weigh between 900 and 1,400 pounds, well within single-syringe capacity with appropriate adjustment. Performance horses in competitive disciplines require attention to extended withdrawal periods as previously discussed. Warmblood-specific genetic conditions such as WFFS do not appear to affect Quest Plus safety, though affected foals rarely survive to require deworming treatment.

Breed-specific genetic conditions affecting metabolism and drug handling warrant consideration even without documented moxidectin-specific issues. Quarter Horses with HYPP may experience electrolyte changes during any stressful episode, including reactions to deworming, though direct moxidectin-HYPP interactions are not established. Horses with liver disease affecting any breed may have altered drug metabolism requiring veterinary guidance. Friesians with their predisposition to certain conditions and Arabians with breed-specific genetic diseases do not appear to have increased moxidectin sensitivity, but any horse with significant systemic illness warrants individual assessment before treatment with this potent combination product.

Within the combination dewormer category, praziquantel combined with ivermectin (Equimax) offers a somewhat safer alternative with similar spectrum coverage but without the larvicidal activity against encysted small strongyle stages. Ivermectin's wider safety margin makes the ivermectin-praziquantel combination more forgiving of dosing variations and appropriate for a broader patient population including foals, debilitated horses, and miniatures. However, ivermectin-based combinations cannot match moxidectin's ability to eliminate encysted larvae, making Quest Plus the preferred choice when larvicidal activity is specifically indicated.

Single-agent moxidectin (Quest) provides the same superior efficacy against encysted larvae and adult nematodes without praziquantel's tapeworm coverage. This formulation may be preferred when tapeworm treatment is not indicated or when administering during seasons when tapeworm transmission is minimal. Conversely, pyrantel pamoate at double the standard dose (Strongid paste at elevated dosing) provides some tapeworm activity through a completely different mechanism, useful when tapeworm treatment is needed but moxidectin contraindicated. However, pyrantel's tapeworm efficacy is less reliable than praziquantel.

Alternative drug classes play essential roles in rotation programs designed to delay resistance development. Fenbendazole (Panacur, Safe-Guard) represents the benzimidazole class, once highly effective but now showing widespread small strongyle resistance on many properties. Pyrantel salts offer a different mechanism useful in rotation, though resistance to this class is also increasing. Oxibendazole provides another option within the benzimidazole class. Strategic rotation incorporating Quest Plus for its unique larvicidal activity, alternating with other classes for routine strongyle control, optimizes parasite management while preserving each drug class's efficacy.

Complementary management strategies extend beyond pharmaceutical rotation to include environmental and diagnostic tools. Fecal egg count monitoring identifies which horses require treatment, tracks drug efficacy, and detects emerging resistance. Pasture management including manure removal, rotational grazing, and avoiding overstocking reduces parasite transmission pressure. These approaches, integrated with strategic pharmaceutical use, provide sustainable parasite control superior to reliance on any single deworming product. Veterinary parasitologists increasingly advocate this comprehensive approach, positioning potent products like Quest Plus as targeted interventions within broader management frameworks rather than routine treatments.